Hope for Huntington's: new pill targets harmful proteins in Long-Term study
NCT ID NCT07537075
First seen Apr 25, 2026 · Last updated May 14, 2026 · Updated 4 times
Summary
This study tests an oral drug called SKY-0515 in 500 adults with Huntington's disease who have already taken it in a previous study. The goal is to see if the drug can safely lower harmful proteins and improve symptoms over time. Participants must be 25 or older and have a genetic confirmation of Huntington's disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUNTINGTON'S DISEASE (HD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Calvary Health Care Bethlehem
Caulfield South, Victoria, 3162, Australia
-
Flinders Medical Centre
Adelaide, South Australia, 5042, Australia
-
The Royal Melbourne Hospital
Parkville, Victoria, 3050, Australia
-
Westmead Hospital
Westmead, New South Wales, 2145, Australia
Conditions
Explore the condition pages connected to this study.